Kisspeptin's Dual Role in Egg Maturation: From Brain Signaling to Direct Ovarian Action | Research

The takeaway

Kisspeptin promotes egg maturation through two pathways — indirectly via brain-pituitary hormones and directly by acting on kisspeptin receptors on the oocyte itself — with clinical applications in IVF.

KPR knockout = ovulation failure
When kisspeptin receptors were removed from mouse oocytes, eggs failed to mature and ovulation did not occur — a condition resembling premature ovarian insufficiency in humans.

What the researchers found

Kisspeptin plays a dual role in oocyte maturation. The well-known indirect pathway works through the brain: hypothalamic kisspeptin neurons stimulate GnRH release, which triggers FSH and LH secretion from the pituitary, driving follicle development and ovulation.

But this review highlights a newer finding: kisspeptin also acts directly on the oocyte itself. Kisspeptins are produced by granulosa cells in ovarian follicles, while kisspeptin receptors are expressed on the oocytes. In mice, loss of kisspeptin receptors in oocytes led to failure of oocyte maturation and ovulation, resembling premature ovarian insufficiency.

In vitro studies in rats, pigs, and sheep confirmed that kisspeptin directly stimulates oocyte maturation by triggering calcium release and activating ERK1/2 signaling. In human clinical trials, kisspeptin-54 has been successfully used to improve oocyte maturation in assisted reproductive technologies.

Why it matters

The discovery that kisspeptin acts directly on eggs — not just through the brain — opens a new therapeutic avenue for fertility treatment. In IVF, triggering final egg maturation is a critical step that currently uses drugs with side effect risks. Kisspeptin offers a potentially safer trigger that works through both central and ovarian pathways, and clinical trials have already shown success in human patients undergoing assisted reproduction.

The numbers in context

KP-54 used in human clinical trials · Mouse KPR knockout = ovulation failure · Ca²⁺ release + ERK1/2 activation in rat oocytes · KP expression peaks during preovulatory surge

How the study worked

Narrative review synthesizing published research on kisspeptin signaling in oocyte maturation across species (mice, rats, pigs, sheep, humans). Covers both the indirect hypothalamic-pituitary pathway and the direct ovarian kisspeptin-oocyte signaling axis. Includes evidence from knockout studies, in vitro oocyte maturation experiments, and human clinical trials.

Who was studied

Cross-species review covering mice, rats, pigs, sheep, and humans, with focus on oocyte maturation and ovulation

What this study cannot tell us

As a review, no new experimental data is presented. Much of the direct ovarian kisspeptin evidence comes from animal models, and the relative contribution of direct vs. indirect kisspeptin signaling during in vivo human oocyte maturation is not fully resolved. Clinical trial data on kisspeptin-54 in assisted reproduction is still limited in scale.

How to read the evidence

Comprehensive narrative review drawing on animal knockout studies, in vitro experiments across multiple species, and early human clinical trial data. Evidence for the direct ovarian pathway is strong in animals but still being established in humans.

When this study was published

Published in 2022, this review captures the latest understanding of kisspeptin's role in reproduction. The field is moving quickly, with ongoing clinical trials of kisspeptin in IVF expected to provide more human data.

The bigger picture

Kisspeptin has gone from an obscure peptide to a central player in reproductive biology in just two decades. This review highlights the latest chapter: the discovery of a direct ovarian role that works independently of the brain. For fertility medicine, this means kisspeptin could offer a more physiological and potentially safer way to trigger egg maturation in IVF — avoiding the ovarian hyperstimulation syndrome that can occur with current methods using hCG.

Questions still open

Can kisspeptin-based IVF triggers fully replace hCG for final oocyte maturation while reducing ovarian hyperstimulation risk?
How much of kisspeptin's clinical effect in IVF comes from direct ovarian action versus the hypothalamic-pituitary pathway?
Could kisspeptin receptor deficiency explain some cases of unexplained infertility in women?

Common questions

How could kisspeptin improve IVF treatment?

Current IVF protocols use hCG to trigger final egg maturation, but this carries a risk of ovarian hyperstimulation syndrome (OHSS). Kisspeptin triggers a more natural hormonal cascade and may directly promote egg maturation through ovarian receptors. Clinical trials have shown it can successfully mature eggs for IVF with potentially fewer side effects.

Does kisspeptin only work through the brain?

No — this is the key new finding. While kisspeptin was originally known for its brain-based role in triggering reproductive hormones, researchers have now shown it also acts directly on eggs in the ovary. Oocytes have kisspeptin receptors, and nearby granulosa cells produce kisspeptin to promote maturation at the right time.

Read the original research

The role of Kisspeptin signaling in Oocyte maturation.

Frontiers in endocrinology, 13, 917464

View on PubMed ↗Publisher’s paper ↗

Citation

Masumi, Saeed; Lee, Eun Bee; Dilower, Iman; Upadhyaya, Sameer; Chakravarthi, V Praveen; Fields, Patrick E; Rumi, M A Karim. (2022). The role of Kisspeptin signaling in Oocyte maturation.. Frontiers in endocrinology, 13, 917464. https://doi.org/10.3389/fendo.2022.917464